Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
Breast cancer is a major health challenge for women worldwide, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancers have a relatively high incidence and are highly aggressive. Targeted therapeutic agents, represented by trastuzumab, have been effective in improving the surviv...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-02-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1492203/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1825206830772518912 |
|---|---|
| author | Xiang Zhang Yulian Yin Qiuting Yu Xinlin Chen Yiqin Cheng |
| author_facet | Xiang Zhang Yulian Yin Qiuting Yu Xinlin Chen Yiqin Cheng |
| author_sort | Xiang Zhang |
| collection | DOAJ |
| description | Breast cancer is a major health challenge for women worldwide, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancers have a relatively high incidence and are highly aggressive. Targeted therapeutic agents, represented by trastuzumab, have been effective in improving the survival rate of HER-2-positive breast cancer patients. However, in clinical applications, this type of targeted drugs exhibits varying degrees of cardiotoxicity, and the mechanism of their cardiotoxicity is currently unclear. In this paper, we classify them into three categories: monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugate (ADCs). We list the evidence of cardiotoxicity for various drugs based on current clinical trials and summarize their corresponding epidemiological profiles. We also discuss the regulation of cardiotoxicity from three perspectives: clinical biomarkers of cardiotoxicity, permissive cardiotoxicity, and the current status of cardiotoxicity regulation. |
| format | Article |
| id | doaj-art-e1fec814f9084832864b6a1e57e58331 |
| institution | Kabale University |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-e1fec814f9084832864b6a1e57e583312025-02-07T05:10:31ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-02-011410.3389/fonc.2024.14922031492203Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugsXiang Zhang0Yulian Yin1Qiuting Yu2Xinlin Chen3Yiqin Cheng4Department of Cardiology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Breast Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Cardiology, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaHospital Administration Office, Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaDepartment of Breast Surgery, Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, ChinaBreast cancer is a major health challenge for women worldwide, and human epidermal growth factor receptor 2 (HER-2)-positive breast cancers have a relatively high incidence and are highly aggressive. Targeted therapeutic agents, represented by trastuzumab, have been effective in improving the survival rate of HER-2-positive breast cancer patients. However, in clinical applications, this type of targeted drugs exhibits varying degrees of cardiotoxicity, and the mechanism of their cardiotoxicity is currently unclear. In this paper, we classify them into three categories: monoclonal antibodies (mAbs), small-molecule tyrosine kinase inhibitors (TKIs), and antibody-drug conjugate (ADCs). We list the evidence of cardiotoxicity for various drugs based on current clinical trials and summarize their corresponding epidemiological profiles. We also discuss the regulation of cardiotoxicity from three perspectives: clinical biomarkers of cardiotoxicity, permissive cardiotoxicity, and the current status of cardiotoxicity regulation.https://www.frontiersin.org/articles/10.3389/fonc.2024.1492203/fullbreast cancerHER-2cardiotoxicitytargeted therapyreview |
| spellingShingle | Xiang Zhang Yulian Yin Qiuting Yu Xinlin Chen Yiqin Cheng Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs Frontiers in Oncology breast cancer HER-2 cardiotoxicity targeted therapy review |
| title | Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs |
| title_full | Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs |
| title_fullStr | Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs |
| title_full_unstemmed | Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs |
| title_short | Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs |
| title_sort | review of the clinical status of cardiotoxicity of her 2 positive breast cancer targeted therapeutic drugs |
| topic | breast cancer HER-2 cardiotoxicity targeted therapy review |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1492203/full |
| work_keys_str_mv | AT xiangzhang reviewoftheclinicalstatusofcardiotoxicityofher2positivebreastcancertargetedtherapeuticdrugs AT yulianyin reviewoftheclinicalstatusofcardiotoxicityofher2positivebreastcancertargetedtherapeuticdrugs AT qiutingyu reviewoftheclinicalstatusofcardiotoxicityofher2positivebreastcancertargetedtherapeuticdrugs AT xinlinchen reviewoftheclinicalstatusofcardiotoxicityofher2positivebreastcancertargetedtherapeuticdrugs AT yiqincheng reviewoftheclinicalstatusofcardiotoxicityofher2positivebreastcancertargetedtherapeuticdrugs |